



The ARRIVE guidelines 2.0: author checklist

The ARRIVE Essential 10

These items are the basic minimum to include in a manuscript. Without this information, readers and reviewers cannot assess the reliability of the findings.

Item	Recommendation	Section/line number, or reason for not reporting
Study design	1 For each experiment, provide brief details of study design including: a. The groups being compared, including control groups. If no control group has been used, the rationale should be stated. b. The experimental unit (e.g. a single animal, litter, or cage of animals).	Method
		Method
Sample size	2 a. Specify the exact number of experimental units allocated to each group, and the total number in each experiment. Also indicate the total number of animals used. b. Explain how the sample size was decided. Provide details of any <i>a priori</i> sample size calculation, if done.	Method
		Method
Inclusion and exclusion criteria	3 a. Describe any criteria used for including and excluding animals (or experimental units) during the experiment, and data points during the analysis. Specify if these criteria were established <i>a priori</i> . If no criteria were set, state this explicitly. b. For each experimental group, report any animals, experimental units or data points not included in the analysis and explain why. If there were no exclusions, state so. c. For each analysis, report the exact value of <i>n</i> in each experimental group.	Method
		Method
		Each result will report <i>n</i> .
Randomisation	4 a. State whether randomisation was used to allocate experimental units to control and treatment groups. If done, provide the method used to generate the randomisation sequence. b. Describe the strategy used to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. If confounders were not controlled, state this explicitly.	Method
		Method
Blinding	5 Describe who was aware of the group allocation at the different stages of the experiment (during the allocation, the conduct of the experiment, the outcome assessment, and the data analysis).	Method
Outcome measures	6 a. Clearly define all outcome measures assessed (e.g. cell death, molecular markers, or behavioural changes). b. For hypothesis-testing studies, specify the primary outcome measure, i.e. the outcome measure that was used to determine the sample size.	Method
		Method
Statistical methods	7 a. Provide details of the statistical methods used for each analysis, including software used. b. Describe any methods used to assess whether the data met the assumptions of the statistical approach, and what was done if the assumptions were not met.	Method: Statistical Analysis
		Method: Statistical Analysis
Experimental animals	8 a. Provide species-appropriate details of the animals used, including species, strain and substrain, sex, age or developmental stage, and, if relevant, weight. b. Provide further relevant information on the provenance of animals, health/immune status, genetic modification status, genotype, and any previous procedures.	Method
		Method
Experimental procedures	9 For each experimental group, including controls, describe the procedures in enough detail to allow others to replicate them, including: a. What was done, how it was done and what was used. b. When and how often. c. Where (including detail of any acclimatisation periods). d. Why (provide rationale for procedures).	Method
		Method
		Method
		Method
Results	10 For each experiment conducted, including independent replications, report: a. Summary/descriptive statistics for each experimental group, with a measure of variability where applicable (e.g. mean and SD, or median and range). b. If applicable, the effect size with a confidence interval.	Method
		Mean $\pm$ standard error of the mean

The Recommended Set

These items complement the Essential 10 and add important context to the study. Reporting the items in both sets represents best practice.

Item		Recommendation	Section/line number, or reason for not reporting
Abstract	11	Provide an accurate summary of the research objectives, animal species, strain and sex, key methods, principal findings, and study conclusions.	
Background	12	a. Include sufficient scientific background to understand the rationale and context for the study, and explain the experimental approach. b. Explain how the animal species and model used address the scientific objectives and, where appropriate, the relevance to human biology.	
Objectives	13	Clearly describe the research question, research objectives and, where appropriate, specific hypotheses being tested.	
Ethical statement	14	Provide the name of the ethical review committee or equivalent that has approved the use of animals in this study, and any relevant licence or protocol numbers (if applicable). If ethical approval was not sought or granted, provide a justification.	Animal experiments were approved by the Animal Ethics Committee of Fuwai Hospital.
Housing and husbandry	15	Provide details of housing and husbandry conditions, including any environmental enrichment.	
Animal care and monitoring	16	a. Describe any interventions or steps taken in the experimental protocols to reduce pain, suffering and distress. b. Report any expected or unexpected adverse events. c. Describe the humane endpoints established for the study, the signs that were monitored and the frequency of monitoring. If the study did not have humane endpoints, state this.	mice were anesthetized with isoflurane inhalation with 2%–5% isoflurane for electrocardiogram and echocardiogram, and their hearts were harvested for histology and immunohistochemistry. As expected, two mice in the group of arrhythmogenic right ventricular cardiomyopathy died due to cardiac failure or arrhythmias We did not establish the humane endpoints in the study.
Interpretation/scientific implications	17	a. Interpret the results, taking into account the study objectives and hypotheses, current theory and other relevant studies in the literature. b. Comment on the study limitations including potential sources of bias, limitations of the animal model, and imprecision associated with the results.	pharmacological inhibition of NLRP3 may inactivate myeloid cell subpopulation associated with ARVC to solve to the inflammation of ARVC. we have identified some key genes involved with the pathogenesis of premature cells (NLRP3 for macrophages and fibroblasts (FIBROS)). Although we have investigated the expression of NLRP3 and FIBROS in ARVC, it is still unclear whether these genes play a role in ARVC. In addition, more mechanistic study should be performed to apply in clinical practice. Especially to clarify the source of the adipocytes and the signals inducing the formation of adipocytes, genetic lineage tracing approaches in the context of ARVC might be helpful in addressing this question. Sources of bias: the results of ARVC generally do not have the robust fully involvement seen in human.
Generalisability/translation	18	Comment on whether, and how, the findings of this study are likely to generalise to other species or experimental conditions, including any relevance to human biology (where appropriate).	the findings of this study are likely to generalise to PKP2 mutant pigs, the ARVC pig model
Protocol registration	19	Provide a statement indicating whether a protocol (including the research question, key design features, and analysis plan) was prepared before the study, and if and where this protocol was registered.	no
Data access	20	Provide a statement describing if and where study data are available.	
Declaration of interests	21	a. Declare any potential conflicts of interest, including financial and non-financial. If none exist, this should be stated. b. List all funding sources (including grant identifier) and the role of the funder(s) in the design, analysis and reporting of the study.	The authors declare that they have no conflict of interest. This work was funded by grants from the National Natural Science Foundation of China (82000225, 82125004).